Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Optimization of Non-Cross-Linked Hyaluronic Acid and Adipose-Derived Mesenchymal Stem Cells for Regenerative Applications: an in Vitro Study.

Kafaei E., Forozesh L., Barghian E., Barghian B., Malekan M., Gholizadeh F.

Laboratory Study on Skin Aging, Chronic Inflammation, published in Cell Biochem Biophys (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Cell Biochem Biophys (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41854982
DOI
10.1007/s12013-026-02007-1

Abstract (original English)

Hyaluronic acid (HA) and adipose-derived mesenchymal stem cells (AD-MSCs) are both promising agents for skin rejuvenation. Combining non-cross-linked HA with AD-MSCs may enhance regenerative outcomes; however, the optimal HA concentration and its compatibility with AD-MSCs remain unclear. This study evaluated AD-MSCs encapsulated in varying concentrations of non-cross-linked HA, including a Proage® HA formulation, to identify the most biocompatible scaffold for regenerative applications. AD-MSCs were isolated from human adipose tissue and characterized using flow cytometry and tri-lineage differentiation. Cells were encapsulated in HA matrices ranging from 2% to 10%, including a Proage® 2% HA formulation. Metabolic activity was assessed using the Alamar Blue assay on Days 1, 3, 5, and 7. Gene expression of COL1A1, COL3A1, LMNA, IL10, TIMP1, MMP1, CD49f, and CD146 was analyzed via qRT-PCR to evaluate extracellular matrix remodeling and inflammatory responses. AD-MSCs maintained high metabolic activity across HA concentrations, with 4% HA demonstrating the highest metabolic activity by Day 5, whereas higher concentrations (>5%) reduced activity. Gene expression analysis showed significant upregulation of COL1A1, COL3A1, LMNA, TIMP1, CD49f, and CD146 in 3D HA conditions compared with 2D culture. Specifically, 4% HA increased COL1A1, LMNA, CD146, and TIMP1 expression, while the Pro

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Hyaluronic AcidHumansMesenchymal Stem CellsAdipose TissueCell DifferentiationCells, CulturedRegenerationMatrix Metalloproteinase 1Tissue Scaffolds

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research